Principal Financial Group Inc Akebia Therapeutics, Inc. Transaction History

Principal Financial Group Inc

$172 Billion
Q3 2024

A detailed history of Principal Financial Group Inc transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 15,777 shares of AKBA stock, worth $30,291. This represents 0.0% of its overall portfolio holdings.

Number of Shares

15,777

Previous 21,113 25.27%

Holding current value

$30,291

Previous $21,000 4.76%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$0.94 - $1.55 $5,015 - $8,270	-5,336 Reduced 25.27%	15,777 $20,000
Q2 2024 Jul 29, 2024	BUY	$0.86 - $1.63 $18,157 - $34,414	21,113 New	21,113 $21,000
Q3 2022 Nov 09, 2022	SELL	$0.3 - $0.46 $75,109 - $115,167	-250,364 Reduced 60.42%	164,028 $52,000
Q2 2022 Aug 10, 2022	BUY	$0.32 - $0.67 $73,424 - $153,733	229,453 Added 124.07%	414,392 $146,000
Q1 2022 May 09, 2022	SELL	$0.72 - $2.93 $53,009 - $215,718	-73,624 Reduced 28.47%	184,939 $132,000
Q4 2021 Feb 09, 2022	SELL	$2.26 - $3.34 $635,667 - $939,438	-281,269 Reduced 52.1%	258,563 $584,000
Q3 2021 Nov 09, 2021	SELL	$2.35 - $3.88 $18,884 - $31,179	-8,036 Reduced 1.47%	539,832 $1.55 Million
Q2 2021 Aug 10, 2021	SELL	$2.83 - $4.2 $71,794 - $106,549	-25,369 Reduced 4.43%	547,868 $2.08 Million
Q1 2021 May 10, 2021	BUY	$2.92 - $5.06 $105,365 - $182,585	36,084 Added 6.72%	573,237 $1.94 Million
Q4 2020 Feb 08, 2021	BUY	$2.22 - $3.78 $894,384 - $1.52 Million	402,876 Added 300.03%	537,153 $1.5 Million
Q3 2020 Nov 06, 2020	BUY	$2.39 - $13.08 $97,375 - $532,918	40,743 Added 43.56%	134,277 $337,000
Q2 2020 Aug 05, 2020	BUY	$6.67 - $13.58 $420,210 - $855,540	63,000 Added 206.33%	93,534 $1.27 Million
Q1 2020 May 12, 2020	BUY	$4.1 - $10.24 $54,050 - $134,993	13,183 Added 75.98%	30,534 $231,000
Q4 2019 Feb 05, 2020	SELL	$3.16 - $6.73 $34,914 - $74,359	-11,049 Reduced 38.9%	17,351 $110,000
Q3 2019 Nov 13, 2019	BUY	$3.55 - $5.4 $37,370 - $56,845	10,527 Added 58.9%	28,400 $111,000
Q2 2019 Aug 12, 2019	BUY	$4.1 - $8.05 $27,322 - $53,645	6,664 Added 59.45%	17,873 $87,000
Q1 2019 May 10, 2019	SELL	$5.41 - $8.73 $8,618 - $13,906	-1,593 Reduced 12.44%	11,209 $92,000
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $69,002 - $117,138	12,802 New	12,802 $71,000

Others Institutions Holding AKBA

# of Institutions

121

Shares Held

54.8M

Call Options Held

291K

Put Options Held

179K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $353M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Account

Principal Financial Group Inc Akebia Therapeutics, Inc. Transaction History